Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Authors
Keywords
-
Journal
LANCET
Volume 402, Issue 10402, Pages 613-626
Publisher
Elsevier BV
Online
2023-06-27
DOI
10.1016/s0140-6736(23)01200-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program
- (2023) Juan Pablo Frías Expert Review of Endocrinology & Metabolism
- Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
- (2022) Naveed Sattar et al. NATURE MEDICINE
- Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity
- (2022) Ali Aminian et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Tirzepatide Once Weekly for the Treatment of Obesity
- (2022) Ania M. Jastreboff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
- (2022) W. Timothy Garvey et al. NATURE MEDICINE
- GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes
- (2022) Nikolaus Marx et al. CIRCULATION
- 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes—2023
- (2022) Nuha A. ElSayed et al. DIABETES CARE
- Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
- (2022) Rola Hammoud et al. Nature Reviews Endocrinology
- Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program
- (2022) Carel W. le Roux et al. Obesity
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
- (2021) Melanie Davies et al. LANCET
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic
- (2021) Andres Acosta et al. Obesity
- Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
- (2021) Sean Wharton et al. DIABETES OBESITY & METABOLISM
- Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis
- (2021) Ali Aminian et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications
- (2021) W Timothy Garvey JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
- (2021) Ildiko Lingvay et al. LANCET
- Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation
- (2021) Alessia Costa et al. Molecular Metabolism
- The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists
- (2020) Shweta Urva et al. DIABETES OBESITY & METABOLISM
- How May GIP Enhance the Therapeutic Efficacy of GLP-1?
- (2020) Ricardo J. Samms et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Cardiovascular outcome trials in obesity: A review
- (2020) John P.H. Wilding et al. Obesity Reviews
- Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity
- (2019) Ali Aminian et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Gastrointestinal Symptoms in Diabetes: Prevalence, Assessment, Pathogenesis, and Management
- (2018) Yang T. Du et al. DIABETES CARE
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
- (2018) Tamer Coskun et al. Molecular Metabolism
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY
- (2016) W. Timothy Garvey et al. Endocrine Practice
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes
- (2013) P. Hollander et al. DIABETES CARE
- Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study
- (2012) Patrick M. O'Neil et al. Obesity
- Self-Monitoring in Weight Loss: A Systematic Review of the Literature
- (2010) Lora E. Burke et al. JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION
- Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis
- (2009) A. N. Fabricatore et al. Obesity Reviews
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started